News
Nov 10, 2023
WARNING: Amador's Official Recruitment
Someone impersonating Amador is trying to commit recruitment scams on the internet. We don't want anyone to fall for this scam. Therefore, ...
May 5, 2023
Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology
Amador Bioscience appoints Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology to accelerate ...
Mar 7, 2023
Dr. Lorin K. Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience’s Board of Directors
Dr. Lorin K Roskos, biopharmaceutical leader and executive, joins Amador Bioscience’s board of directors.
Nov 2, 2022
Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland
Celebrating its strategic milestone opening in an emerging biotech hub, Amador welcomed many distinguished guests to its new facilities in ...
Oct 28, 2022
Amador Bioscience and BIOMED Finalize Collaboration
Amador Bioscience and BIOMED announce collaboration to support clinical studies with omics-based biomarker discovery capabilities.
Oct 21, 2022
Amador Bioscience Appoints Dr. Howard Yuwen as Senior Vice President of Global Regulatory Affairs
Amador Bioscience, announces the appointment of Dr. Howard Yuwen to Senior Vice President of Global Regulatory Affairs.
Sep 21, 2022
More Than Four Million Euros for Third-phase Expansion of Netherland-based BioVille
Amador Bioscience announces its arrival at BioVille, an incubator for life science organizations that recently received funding to expand ...
Sep 12, 2022
Amador Bioscience and Ann Arbor Pharmacometrics Group Further Align to Take End-to-End Drug Development Into the Future
Ann Arbor Pharmacometrics Group (A2PG) joined forces with Amador Bioscience to strengthen its global leadership in clinical pharmacology.
Mar 10, 2022
Amador Bioscience Establishes Clinical Division in Hangzhou
On March 10, 2022, we announced the establishment of a new clinical business unit in Hangzhou. Patrick Hu, MD, was appointed as the chief ...
Jan 10, 2022
Dr. Meina Liang Joins Amador Bioscience as Chief Technology Officer
Amador Bioscience announced the appointment of Dr. Meina Liang, PhD, a world-renowned expert in innovative drug R&D and bioanalysis, as ...
Dec 31, 2021
Translational Science and Clinical Pharmacology CRO, Amador Bioscience, Announces the Completion of Over $60 Million in Series B+ Financing
The new round of financing was led by Heyu Capital (MSA), and the existing shareholders Sequoia China, Hillhouse Ventures, and Kaifeng ...
Dec 24, 2021
Amador Bioscience Acquires Ann Arbor Pharmacometrics Group (A2PG)
Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed the acquisition of ...
Nov 28, 2021
Amador Bioscience Expands to Belgium
The Biopharmaceutical Ecosystem Development Seminar goal was to discuss how to promote the development of new drug research and growth of ...
Nov 4, 2021
Strategic Cooperation Agreement Between Amador Bioscience and Belgian Government
Amador Biotech signed a strategic cooperation with the Belgian government. Tom Vandeput, Deputy Governor of Limburg Province in Belgium, ...
